SN BioScience

Pipeline	Indication		Research		Partnering
SNB-101 (Nanoparticle)	Solid Tumor	Small Cell Lung Cancer	Late 2028 Phase 1b/2 (pivotal, mono) Phase 1b (combo /w IO)	Orphan Drug Fast Track Orphan Drug	Open for Collaboration
		Pancreatic Cancer	Phase 1b	Orphan Drug
		Gastric Cancer	Phase 1b	Orphan Drug
		Solid Tumor 4	Phase 1b
		Solid Tumor 5	Phase 1b
SNA-001 (Nanoparticle)	Pancreatic Cancer Breast Cancer Non-Small Cell Lung Cancer		2027 Phase 1 (pivotal)
SNA-002 (Liposome)	Pain		2029 Preclinical
SNA-003 (Complex)	Diabetic		2029 Preclinical
SNA-003 (Complex)	Obesity		2029 Phase 1

SNB-101

SNB-101 is the first injectable formulation with SN-38 (7-ethyl-10-hydroxycamptothecin) that is the most potent chemotherapeutic agent, and has recently become famous as it is widely used as the payload of ADC. SNB-101 adopts polymeric micelle technology for efficient delivery of drug, SN-38, and has been shown to penetrate particularly well to lung cancer in preclinical and early clinical trial.
SNA-001

SNA-001 is a generic version of Abraxane®(Albumin bound paclitaxel).
Our company have developed a simple and highly productive manufacturing process compared to other nab-paclitaxel competitors through an innovative manufacturing technology.
SNA-002

SNA-002 is liposomal formulation for pain after surgery especially for knees and shoulders.
It releases drug slowly for 3 days to maintain a constant drug concentration in blood, thereby stably managing pain for 3 days after surgery.
SNA-003

SNA-003 is a new formulation with GLP-1 agonist intended for metabolic disease such as diabetes, MASH, and obesity.
SNA-003 have shown improved pharmacokinetic profile in preclinical study, which means relatively low peak to trough ratios (Cmax/Cmin ratios) compared to conventional SC formulation. Our company expected that SNA-003 can reduce the rate of patients discontinuing medication due to adverse effect caused by high variation of drug concentration in blood.

About us